Your session is about to expire
← Back to Search
Apalutamide for Prostate Cancer
Study Summary
This trial is testing a new treatment for prostate cancer that has come back after surgery. They are testing to see if it can help people live longer without the cancer progressing.
- Prostate Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
To what extent is Apalutamide detrimental to one's health?
"Due to limited data supporting efficacy, Apalutamide was rated a 2 for safety."
How widespread is this clinical trial's presence?
"Five separate sites are currently participating in this trial, located in Omaha, Durham, Winston-Salem and other cities. When selecting a location to participate from it is beneficial to consider the closest one for convenience of travel."
Has Apalutamide been investigated in any prior clinical experiments?
"At the current time, 359 Apalutamide-related studies are ongoing globally. Of these trials, 140 have progressed to Phase 3. 24762 clinical trial sites around the world offer this medication, with a majority of them located in Fuzhou City, Fujian Province."
Is this experiment still actively recruiting participants?
"At this time, recruitment for the trial is not occurring. The original posting was on March 28th 2018 and it has since been revised as of November 10th 2022. If you are looking to participate in a medical study, there are 1321 active studies related to prostate cancer and 359 concerning Apalutamide that need participants."
In what diseases is Apalutamide frequently prescribed?
"Apalutamide has the potential to treat multiple neoplasms, as well as prostate cancer non-metastatic and any cases of resistance or advance directives associated with hormone therapy."
What is the enrollment rate for this research endeavor?
"This experiment is no longer recruiting participants. It was first publicized on March 28th 2018 and its information was last updated on November 10th 2022. Currently, 1321 trials related to prostate cancer are enrolling patients, with 359 looking for Apalutamide candidates specifically."
Share this study with friends
Copy Link
Messenger